Biologics, like monoclonal antibodies and viral vectors, make up rapidly growing classes of drugs. They are also critical research tools and essential for the development of many new diagnostics.
While chromatography has been a mainstay of small molecules, these larger, bulky biologics require a new approach to downstream manufacturing. Isolere Bio was founded with the vision of simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs.
We are currently focused on developing this technology for the manufacturing of antibodies and adeno-associated virus (AAV). We are working to develop a low-cost, high throughput, and scalable purification platform and are actively seeking research collaborators in development and validation.
Our product is made entirely recombinantly in E. coli and has no synthetic scaffold. This eliminates the cost of the solid support and chemical conjugation.
Our process scales linearly, providing a seamless transition from bench to industry scale production.
EASE OF USE
Our technology requires a simple tangential flow filtration (TFF) setup rather than complex chromatography equipment.
From high throughput 96-well plates, to all-in-one kits, to bulk reagent, our technology can be tailored to suit your needs.
Complete an entire round of purification with TFF in under 30 minutes! High flux will eliminate the capture step bottleneck and permeate control enables seamless development of a continuous downstream processes.
Our reagent binds and elutes the target in solution, eliminating the mass transfer constraints of traditional packed bed chromatography
Chromatography-free solutions for the purification of biological therapeutics such as monoclonal antibodies and viral gene delivery vectors.
May 5, 2021
Isolere announces the closing of a $7M Series Seed financing round and is honored to join the Northpond Ventures portfolio. Read more here.
May 4, 2021
Isolere receives a Fast-Track award from the NIH to support its AAV manufacturing technology.
May 3, 2021
Isolere welcomes Yi Wang, PhD, MBA to the team as VP of Business Development. Welcome, Yi!
THE ISOTAG TECHNOLOGY
This process is highly platform-able! Contact us to discuss custom reagent development to your therapeutic of interest. By replacing the antibody-binding domain with a different capture domain at the gene level, this versatile technology can be applied to other biotherapeutics.
FOUNDER & CHAIRMAN OF THE BOARD
Ashutosh Chilkoti, PhD
FOUNDER & CHIEF SCIENTIFIC ADVISOR
Kelli Luginbuhl, PhD
FOUNDER & CHIEF EXECUTIVE OFFICER
Adam Wieschhaus, PhD, CFA
BOARD OF DIRECTORS
Michael Dzuricky, PhD
CHIEF SCIENTIFIC OFFICER
Rich McGivney, CPA
CHIEF FINANCIAL OFFICER
Yi Wange, PhD, MBA
VP Business Development
Isolere is hiring!
We are looking to fill several key positions:
Lead Scientist of mRNA R&D Program - lead the application of our technology to improve mRNA manufacturability and modification efficiency (posting)
Lead Scientist of Viral Vector R&D Program - lead the application of our technology to viral vectors, including lentivirus, retrovirus, adenovirus, and others (posting)
Lead Engineer of Downstream Processing - take on a key role in helping us to develop robust, scalable, and platform process solutions for diverse biologics (posting)
Lead Scientist of Phage Display Program - help build an innovative phage display program for rapidly and robustly identifying high performance affinity reagents (posting)
Lab and Office Manager - Assist management team with scheduling, accounting, and HR/recruiting. Manage the lab and office operations, plan events to build company culture, and implement methodologies to streamline company efficiency and organization (posting)